Sponsor: UCB
Protocol Number: SL0043
|
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity. |
Detailed Information: Here
To learn more or see if you qualify: Click Here
/assets/production/practices/c1f0c98a14a26efc3f61c530443c39569f27073b/images/2610814.jpg)